Rivastigmine
|
|
|
- CAS-Nr.
- 123441-03-2
- Englisch Name:
- Rivastigmine
- Synonyma:
- RIVASTIGMINE HYDROGEN TARTRATE;mine;EXELON;Rivastigmine base;Rivastig;Kabaratin;cabalatine;Revastigmine;RIVASTIGMINE;RivastigiMine
- CBNumber:
- CB8328151
- Summenformel:
- C14H22N2O2
- Molgewicht:
- 250.34
- MOL-Datei:
- 123441-03-2.mol
|
Rivastigmine Eigenschaften
- alpha
- D20 -32.1° (c = 5 in ethanol)
- Siedepunkt:
- 316.2±34.0 °C(Predicted)
- Dichte
- 1.038±0.06 g/cm3(Predicted)
- Flammpunkt:
- 145℃
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- Chloroform (Sparingly), Ethyl Acetate (Slightly)
- Aggregatzustand
- Powder
- pka
- pKa 8.99 (Uncertain)
- Farbe
- Colorless to light yellow
- Major Application
- pharmaceutical (small molecule)
- InChI
- InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
- InChIKey
- XSVMFMHYUFZWBK-NSHDSACASA-N
- SMILES
- C(OC1=CC=CC([C@@H](N(C)C)C)=C1)(=O)N(CC)C
- CAS Datenbank
- 123441-03-2(CAS DataBase Reference)
Rivastigmine Chemische Eigenschaften,Einsatz,Produktion Methoden
History
Rivastigmine was discovered by Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem and sold to Novartis by Yissum for commercial development. Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease.
Verwenden
Antidepressant
Definition
ChEBI: A carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor.
Allgemeine Beschreibung
Rivastigmine (Exelon, EA 713) is apseudoirreversible noncompetitive carbamate inhibitor ofAChE. Although the half-life is approximately 2 hours,the inhibitory properties of this agent last for 10 hours becauseof the slow dissociation of the drug from the enzyme.The Food and Drug Administration (FDA) approved its usein mild-to-moderate Alzheimer disease in April 2000. InJuly 2007, rivastigmine was granted approval for use inmanaging mild-to-moderate dementia associated withParkinson disease.
Pharmakokinetik
Rivastigmine is a centrally selective, arylcarbamate AChEI that was approved in 2000 for oral administration in the treatment of AD. It has an
elimination half-life of 1.4 to 1.7 hours but is able to inhibit AChE for up to 10 hours. Because of the slow dissociation of the carbamylated
enzyme, it has been referred to as a pseudo-irreversible AChEI. Like donepezil, rivastigmine exhibits a low level of hepatotoxicity. It is
rapidly and extensively hydrolyzed in the CNS by cholinesterase with minimal involvement of CYP450. The phenolic metabolite is excreted
primarily via the kidneys.
Stoffwechsel
Rivastigmine is the tertiary amines that
are rapidly absorbed from the gastrointestinal tract, as
are tacrine, donepezil, and galanthamine, whereas quaternary
ammonium compounds are poorly absorbed
after oral administration. Nevertheless, quaternary ammonium
compounds like neostigmine and pyridostigmine
are orally active if larger doses are employed.
Only the quaternary ammonium inhibitors do not readily
enter the CNS. Because of their high lipid solubility
and low molecular weight, most of the organophosphates
are absorbed by all routes of administration;
even percutaneous exposure can result in the absorption
of sufficient drug to permit the accumulation of
toxic levels of these compounds.
Rivastigmine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Rivastigmine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 353)Lieferanten
123441-03-2()Verwandte Suche:
- (S)-N-Ethyl-N-Methyl- 3-[1-(diMethylaMino)ethyl]- phenyl carbaMate
- S-RivastigMine
- CarbaMic acid, N-ethyl-N-Methyl-, 3-[(1S)-1-(diMethylaMino)ethyl]phenyl ester
- RivastigiMine
- bis(sulfanylidene)ruthenium
- (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
- Revastigmine
- N-Ethyl-N-methylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl-ester
- Revastigmine (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
- Rivastigmine Base/ Tartrate
- EXELON
- RIVASTIGMINE
- RIVASTIGIMINE(FORR&DONLY)
- 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
- Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
- 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
- Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
- Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-
- Ena 713 free base
- Unii-pki06m3iw0
- Rivastigmine (0.1 mL)
- (S)-3-[1-(diMethylaMino)ethyl]phenyl N-ethyl-N-MethylcarbaMate
- Rivastigmine for system suitability CRS
- Rivastig
- Rivastigmine USP/EP/BP
- Rivastigmine intermediate,Rivastigmine
- Rivastigmine (1604836)
- Benzo[b]thiophene-2-carboxylicacid,3-chloro-5,10-dimethoxy-,methylester
- Rivastigmine Impurity
- Rivastigmine Monomer
- cabalatine
- Kabaratin
- Rivastigmine, 10 mM in DMSO
- RIVASTIGMINE USP
- Rivastigmine (S-Rivastigmine)
- mine
- Rivastigmine base
- RIVASTIGMINE HYDROGEN TARTRATE
- 123441-03-2
- 320-67-4
